⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AGEN News
Agenus Inc.
Agenus宣布BOT+BAL联合免疫疗法用于MSS或pMMR转移性结直肠癌的全球3期BATTMAN试验完成首例患者入组
businesswire.com
AGEN
Agenus gibt die Aufnahme des ersten Patienten in die globale Phase-3-Studie BATTMAN bekannt, in der die Immuntherapie-Kombination aus BOT und BAL bei metastasiertem kolorektalem Karzinom der MSS- oder pMMR-Gruppe untersucht wird
businesswire.com
AGEN
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
businesswire.com
AGEN
Agena Bioscience Announces Launch of the CFTR 100+ Panel on the MassARRAY ® System
businesswire.com
AGEN
Form 8-K
sec.gov
AGEN
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
businesswire.com
AGEN
Form 8-K
sec.gov
AGEN
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
businesswire.com
AGEN
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
businesswire.com
AGEN
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
businesswire.com
AGEN